The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
KD025 granted Breakthrough Therapy Designation for the treatment of patients with chronic GvHD
KD025 has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic graft-versus-host disease (cGvHD) after failure of two or more lines of systemic therapy.
KD025, a Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, binds to and inhibits the serine/threonine kinase activity of ROCK2 thus blocks the signaling pathway which plays major roles in pro- and anti-inflammatory immune responses. The FDA granted orphan drug designation to KD025 for the treatment of cGvHD in October 2017.
This decision by the FDA was based on data from an ongoing phase II, dose-escalation, open-label study (KD025-208), which is evaluating the safety, tolerability, and activity of KD025 in patients with cGvHD. Preliminary results from the study were presented at the 23rd Congress of the European Hematology Association (EHA) in June 2018; and at 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in March 2018.
References